We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Vibrational Microspectroscopy Detects Presence of Metastatic Cancer Cells

By Labmedica staff writers
Posted on 19 May 2008
An automatic method based on vibrational microspectroscopy identifies the presence of metastatic cancer cells without the need for staining, and without human input.

The method aids classical cytology (where visual inspection is used to detect changes in the morphology of cells obtained from bodily fluids, exfoliation, or thin needle biopsy) and classical pathology (where stained tissue sections are examined visually). More...
As disease changes the chemical composition of the cell, the newly developed instrument is able to detect variations in cellular properties without the need to stain the slides and inspect them visually.

The machine-based and computer-interpreted technology, which enhances the accuracy and alleviates the physical strain on the human observer, was developed by scientists from the department of chemistry and chemical biology and the Center for Subsurface Sensing and Imaging Systems (CenSISS) at Northeastern University (Boston, MA, USA). "The idea behind the methodology is to examine the chemical composition of cells, as opposed to relying solely on the morphology,” said Prof. Max Diem from the chemistry and chemical biology department. "Abnormalities in exfoliated cells, for instance in Pap smears, can be difficult to discern visually, however, by looking at the biochemical composition of the cell with the help of vibrational spectroscopy, we can detect specific cellular changes indicating cancer.”

The investigators are working on developing an operating room-based instrument that will produce a diagnosis of breast cancer cells in the axillary lymph nodes within 15 minutes after excision. The goal is to produce instrumentation and software that can analyze lymph node sections in the operating room, and provide the surgeon with an objective diagnosis of the spread of disease.


Related Links:
Northeastern University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.